Skip to main content

Take action against Alzheimer’s

Do you want to take action against Alzheimer’s, just like me? See below the full overview of our studies.

What we’ve achieved so far

75+

Trials

250+

Participants

3

Locations

Our Alzheimer’s trials

Filter

Alzheimer's

SHINE

The goal of this study is to evaluate how safe and effective the new drug CT1812 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug CT1812 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer’s disease

durationApproximately 9 months

locationAmsterdam, Den Bosch and Zwolle

Alzheimer's

SHINE

The goal of this study is to evaluate how safe and effective the new drug CT1812 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug CT1812 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer’s disease

durationApproximately 9 months

locationAmsterdam, Den Bosch and Zwolle

Alzheimer's

Treeway

The goal of this study is to evaluate how safe and effective the new drug TW001 is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the new drug TW001 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug consists of granules which are dissolved in water.

audience55 - 80 years

levelEarly stage Alzheimer's disease

durationApproximately 17 weeks

locationAmsterdam and Den Bosch

Alzheimer's

Alnylam

The goal of this study is to evaluate how safe and effective the new drug ALN-APP is for the treatment of participants with MCI or mild dementia due to early onset Alzheimer’s disease, where the disease began before the participant was 65 years old. The study compares the effect of the new drug ALN-APP with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an injection into the fluid surrounding the spinal cord.

audience18+

levelAlzheimer’s or mild dementia due to early onset Alzheimer’s disease

duration152 weeks

locationAmsterdam

Alzheimer's

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

Alzheimer's

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle

Let us know how we can help you

Do you have any questions or would you like to know more about one of our studies? Contact us by phone or email. We are happy to help you.

What do our participants say?

“The most important thing is that there is a solution.”

“With my participation, I may also help others,” says Mr. Arts, one of our participants.

Our partners

Our mission is to eliminate brain diseases, but we cannot do that alone. That is why we work together with leading partners.